GLP-1 RAs not tied to diabetic retinopathy risk, study shows

Researchers analyzed data from the FDA Adverse Event Reporting System between April 2005 and September 2017 and found that older diabetes patients who used GLP-1 receptor agonists were not at an increased risk for diabetic retinopathy. The findings in Diabetes Care revealed that 263 of the 389 GLP-1 receptor agonist-related DR events were associated with exenatide, 82 with liraglutide, 28 with dulaglutide and 16 with albiglutide.

Endocrinology Advisor (1/1)